{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:43:00Z","timestamp":1760784180750,"version":"3.37.3"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000121","name":"Division of Mathematical Sciences","doi-asserted-by":"publisher","award":["DMS-1224362"],"award-info":[{"award-number":["DMS-1224362"]}],"id":[{"id":"10.13039\/100000121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000121","name":"Division of Mathematical Sciences","doi-asserted-by":"publisher","award":["DMS-1349724"],"award-info":[{"award-number":["DMS-1349724"]}],"id":[{"id":"10.13039\/100000121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000147","name":"Division of Civil, Mechanical and Manufacturing Innovation","doi-asserted-by":"publisher","award":["CMMI-1362236"],"award-info":[{"award-number":["CMMI-1362236"]}],"id":[{"id":"10.13039\/100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000147","name":"Division of Civil, Mechanical and Manufacturing Innovation","doi-asserted-by":"publisher","award":["CMMI-1362236"],"award-info":[{"award-number":["CMMI-1362236"]}],"id":[{"id":"10.13039\/100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1005129","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T17:41:49Z","timestamp":1476985309000},"page":"e1005129","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Optimized Treatment Schedules for Chronic Myeloid Leukemia"],"prefix":"10.1371","volume":"12","author":[{"given":"Qie","family":"He","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6561-3647","authenticated-orcid":true,"given":"Junfeng","family":"Zhu","sequence":"additional","affiliation":[]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[]},{"given":"Jasmine","family":"Foo","sequence":"additional","affiliation":[]},{"given":"Kevin Zox","family":"Leder","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"e55717","DOI":"10.1371\/journal.pone.0055717","article-title":"Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era","volume":"8","author":"Z Iqbal","year":"2013","journal-title":"PloS ONE"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"CH Jamieson","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"ref4","first-page":"2084","article-title":"Mathematical model of granulocytopoiesis and chronic myelogenous leukemia","volume":"51","author":"A Fokas","year":"1991","journal-title":"Cancer research"},{"issue":"7046","key":"ref5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"F Michor","year":"2005","journal-title":"Nature"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"e27682","DOI":"10.1371\/journal.pone.0027682","article-title":"Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia","volume":"6","author":"K Leder","year":"2011","journal-title":"PloS ONE"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mbs.2010.06.005","article-title":"Optimal control for resistance and suboptimal response in CML","volume":"227","author":"B A\u00efnseba","year":"2010","journal-title":"Mathematical Biosciences"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia","volume":"4","author":"NL Komarova","year":"2009","journal-title":"PLoS ONE"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"e12300","DOI":"10.1371\/journal.pone.0012300","article-title":"Optimizing combination therapies with existing and future CML drugs","volume":"5","author":"AA Katouli","year":"2010","journal-title":"PloS ONE"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte\u2013colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"A Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"F Guilhot","year":"2007","journal-title":"Blood"},{"key":"ref12","first-page":"89","article-title":"Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib","volume":"3","author":"R Swords","year":"2009","journal-title":"Drug Design, Development and Therapy"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0025-5564(90)90021-P","article-title":"Role of optimal control theory in cancer chemotherapy","volume":"101","author":"GW Swan","year":"1990","journal-title":"Mathematical Biosciences"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10479-011-0869-4","article-title":"A survey of optimization models on cancer chemotherapy treatment planning","volume":"221","author":"J Shi","year":"2014","journal-title":"Annals of Operations Research"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1142\/2048","article-title":"Optimal control of drug administration in cancer chemotherapy","author":"R Martin","year":"1993"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/jtbi.1996.0253","article-title":"Dynamic multidrug therapies for HIV: a control theoretic approach","volume":"185","author":"LM Wein","year":"1997","journal-title":"Journal of Theoretical Biology"},{"article-title":"Switching in systems and control","year":"2012","author":"D Liberzon","key":"ref17"},{"article-title":"Integer and combinatorial optimization","year":"1999","author":"GL Nemhauser","key":"ref18"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"e1000503","DOI":"10.1371\/journal.pcbi.1000503","article-title":"Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib","volume":"5","author":"J Foo","year":"2009","journal-title":"PLoS Computational Biology"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3324\/haematol.2013.085977","article-title":"Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib","volume":"99","author":"A Olshen","year":"2014","journal-title":"Haematologica"},{"key":"ref21","first-page":"1","article-title":"Seminars in hematology","volume":"vol. 25","author":"A Strife","year":"1988"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2012.0009","article-title":"Chronic myelogenous leukemia","volume":"10","author":"S O\u2019Brien","year":"2012","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"S Redaelli","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.leu.2402444","article-title":"Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia","volume":"16","author":"TL Holyoake","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLK.2008.n.017","article-title":"Chronic myeloid leukemia: origin, development, response to therapy, and relapse","volume":"2","author":"D Dingli","year":"2008","journal-title":"Clinical Leukemia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jtbi.2011.10.017","article-title":"Neutrophil dynamics in response to chemotherapy and G-CSF","volume":"293","author":"C Zhuge","year":"2012","journal-title":"Journal of Theoretical Biology"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"H Zhou","year":"2015","journal-title":"Protein & cell"},{"key":"ref28","unstructured":"IBM. IBM ILOG CPLEX: high-performance mathematical programming engine; 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www-01.ibm.com\/software\/in\/integration\/optimization\/cplex\/\" xlink:type=\"simple\">http:\/\/www-01.ibm.com\/software\/in\/integration\/optimization\/cplex\/<\/ext-link>."},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2010.034173","article-title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis","volume":"96","author":"S Soverini","year":"2011","journal-title":"Haematologica"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:22:31Z","timestamp":1589041351000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005129"}},"subtitle":[],"editor":[{"given":"Natalia L.","family":"Komarova","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1005129","relation":{},"ISSN":["1553-7358"],"issn-type":[{"type":"electronic","value":"1553-7358"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}